We are a dynamic team of experts in drug research that deliver unique, customized solutions for your specific needs.
Biometrics forms a centralized, global model that integrates Portfolio Management, Biostatistics & Programming, and Data Operations.
Our Biometrics organization starts with the end in mind, tracking backward along the regulatory pathway to ensure the data are reported, displayed and captured in the most appropriate manner.
This multidisciplinary team of top industry experts works closely with clients to develop cost-effective, real-world solutions that supports their personal needs and complies with global data and reporting requirements.Learn about the PRA’s experts charged with monitoring clinical trial data.
Biometrics’ organized team structure provides more effective communication and increased accountability in ensuring that projects stay on track, on time, and within budget.
Area of Expertise
Biostatistics & Programming
Clinical Systems Management
Our propriety technology and innovative delivery platforms automate tasks that have traditionally involved manually writing and validating programs. These comprehensive and flexible systems replace these outdated, manually programmed processes with automated, reusable programs for data extraction, data transformation, statistical reporting and electronic publishing, resulting in significant process savings, streamlined documentation, and improved quality.
Learn more about our extensive expertise in data management.
PRA On Time in Global Data Management Project
PRA Health Sciences performed data management activities for this project while the client was responsible for all other services, including site…
PRA Cool Under Deadline Pressure
PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based…
PRA Revs Up Multiple Myeloma Study
A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug.…
PRA Health Sciences Investor Relations